Molina Healthcare price target lowered to $283 by TD Cowen on elevated costs

Molina Healthcare (NYSE:MOH) has experienced significant downward revisions to its 2025 and 2026 earnings per share forecasts and price targets from multiple firms, including TD Cowen, Morgan Stanley, UBS, and Barclays. This follows the company's pre-announced Q2 2025 earnings miss and a lowered full-year 2025 EPS guidance ($21.50-$22.50) due to persistently elevated medical utilization and related cost pressures across its Medicaid, Health Insurance Exchange, and Medicare segments. While TD Cowen maintained a Buy rating despite the cuts, Morgan Stanley downgraded the stock, reflecting increasing analyst caution regarding Molina's profitability outlook amidst these trends.

Analysis

Molina Healthcare (MOH) is facing significant headwinds from elevated medical utilization, leading to a material downward revision of its financial outlook and a wave of analyst price target cuts. The company pre-announced second-quarter 2025 earnings per share of $5.50, falling short of the $6.20 consensus, and subsequently lowered its full-year 2025 EPS guidance to a range of $21.50-$22.50 from a prior forecast of over $24.50. This revision is driven by persistent cost pressures across all its business lines—Medicaid, Medicare, and the Health Insurance Exchange—which are expected to continue through the year. In response, Morgan Stanley downgraded the stock to Equalweight from Overweight, while TD Cowen, UBS, and Barclays all reduced their price targets, with TD Cowen's estimate falling to $283 from $369. Despite these challenges and the stock trading near its 52-week low, TD Cowen maintained a Buy rating, projecting a rebound to 14% earnings growth in 2026. The core issue is a rising medical loss ratio, which TD Cowen now projects at 89.5% for 2025, reflecting a fundamental dislocation between premium rates and medical cost trends that is eroding profitability.

Key Decisions for Investors

• Investors should closely monitor Molina's reported Medical Loss Ratio in subsequent quarters, as this is the key metric indicating whether the cost pressures driving the earnings downgrade are intensifying or abating.
• Given the stock is trading near its 52-week low at a 10.4x P/E ratio, value-oriented investors might consider the current price a potential long-term entry point, but this requires a high tolerance for near-term volatility and a belief that the current cost trends are temporary.
• The broad-based analyst downgrades and price target reductions signal a significant negative shift in sentiment, suggesting that momentum-focused investors should exercise caution until there is clear evidence of stabilization in medical costs and a halt to downward earnings revisions.